AU7533194A - Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism - Google Patents

Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism

Info

Publication number
AU7533194A
AU7533194A AU75331/94A AU7533194A AU7533194A AU 7533194 A AU7533194 A AU 7533194A AU 75331/94 A AU75331/94 A AU 75331/94A AU 7533194 A AU7533194 A AU 7533194A AU 7533194 A AU7533194 A AU 7533194A
Authority
AU
Australia
Prior art keywords
postaggression
agonists
metabolism
inhibiting
effective alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU75331/94A
Inventor
Hans-Michael Brecht
Christiane Goeters
Martin Kuhmann
Norbert Mertes
Joseph Zander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU7533194A publication Critical patent/AU7533194A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU75331/94A 1993-07-29 1994-07-27 Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism Abandoned AU7533194A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19934325491 DE4325491A1 (en) 1993-07-29 1993-07-29 Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism
DE4325491 1993-07-29
PCT/EP1994/002475 WO1995003798A2 (en) 1993-07-29 1994-07-27 USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM

Publications (1)

Publication Number Publication Date
AU7533194A true AU7533194A (en) 1995-02-28

Family

ID=6494011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75331/94A Abandoned AU7533194A (en) 1993-07-29 1994-07-27 Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism

Country Status (4)

Country Link
EP (1) EP0719139A1 (en)
AU (1) AU7533194A (en)
DE (1) DE4325491A1 (en)
WO (1) WO1995003798A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024411A1 (en) * 1997-11-05 1999-05-20 The University Of Melbourne Receptor with an affinity for compounds of the oxazoline class

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2196792A1 (en) 1994-08-04 1996-02-15 Yoon T. Jeon Novel benzimidazole derivatives
KR19980702511A (en) * 1995-02-28 1998-07-15 크라우더 티 알 Use of Moxonidine to Treat Atherosclerosis
EP0914128A1 (en) * 1996-06-06 1999-05-12 Eli Lilly And Company Formulation and method for treating congestive heart failure
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
DE19938825A1 (en) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Active ingredient combination with clonidine
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024411A1 (en) * 1997-11-05 1999-05-20 The University Of Melbourne Receptor with an affinity for compounds of the oxazoline class

Also Published As

Publication number Publication date
WO1995003798A2 (en) 1995-02-09
EP0719139A1 (en) 1996-07-03
WO1995003798A3 (en) 2001-05-03
DE4325491A1 (en) 1995-02-02

Similar Documents

Publication Publication Date Title
AU2067892A (en) Corrosion inhibitors
AU693802B2 (en) Agent for transdermal application containing gestoden esters
AU4623193A (en) Corrosion inhibition composition
AU6722194A (en) Novel medical use for gaba agonists
AU5325094A (en) Corrosion monitor system
AU3428393A (en) Use of polyamines as ionic-channel regulating agents
AU6803594A (en) Phenylcyclopropane compounds and their use as camp and tnf inhibitors
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU648907B2 (en) Corrosion inhibitors
AU1105495A (en) Device for the continuous casting of steel
AU1246995A (en) Alpha-quaternary-alpha-amino acids for use as cns agents
AU7184994A (en) Imidazole derivatives as therapeutic agents
AU7150991A (en) Aromatase inhibitors
AU1997197A (en) Device for in-line surface-hardening of products
AU694663B2 (en) Agents for use against parasitic protozoa
AU5323694A (en) 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
AU7533194A (en) Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism
AU6723294A (en) Use of simmondsine
AU4415797A (en) New pde iv inhibitors: "bis-compounds"
AU1850095A (en) Inhibitors of kynureninase
HU9402538D0 (en) Pharmaceutical composition and optical isomerization inhibitor
AU4436196A (en) Benzimidazoles as inhibitors of calcitriol metabolism
AU5118493A (en) Aromatase inhibitor
AU4958293A (en) Agent for preventing damages due to termites
AU5865794A (en) Active oxygen inhibitor composition